LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

Published 2018 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume 29, Issue suppl_8, Pages -

Publisher

Oxford University Press (OUP)

Online

2018-10-25

DOI

10.1093/annonc/mdy424.037

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Create your own webinar